A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: You, Byung Chul, Kim, Young Seok, Kim, Hun il, Kim, Se Hun, Park, Seung Sik, Seo, Yu Ri, Kim, Sang Gyune, Lee, Se Whan, Kim, Hong Soo, Jeong, Soung Won, Jang, Jae Young, Kim, Boo Sung
Format: Artigo
Idioma:Inglês
Publicat: The Korean Association for the Study of the Liver 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467430/
https://ncbi.nlm.nih.gov/pubmed/23091807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2012.18.3.272
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars